

# Optimizing Oncology

---


# Treatment Plans

John Heeren,  
MS, RPh

David Turberville,  
PharmD, BCOP

# The Valley Hospital

- 
- Part of Valley Health System, Ridgewood, NJ
    - The Valley Hospital
    - Valley Home Care
    - Valley Medical Group



# THE VALLEY HOSPITAL



- 451 bed acute-care, not-for-profit community Hospital in Northern New Jersey
- Over 1,100 Practitioners/Providers (MD, DO, PA, APN)
- Over 3,700 Employees
- 41,345 admissions (2020)
- 51,792 emergency department visits (2020)
- 3,528 births (2020)
- Affiliated with Mount Sinai Health System in New York City (32 km away)

# THE "NEW" VALLEY HOSPITAL

---



- “A” patient safety grade from The Leapfrog Group
- Magnet Designation for Nursing Excellence since 2003
- Beacon Award designations for The Valley Hospital's Intensive Care, Neonatal Intensive Care, Coronary Care, Cardiac Surgery and Intermediate Care units
- Currently constructing a new, 372 bed hospital, opening April 2024

# Meditech and Valley Health System

---

- MAGIC: 1995 – 2015
- 6x: 2015 – 2018
- Expanse: 2018 – Present
- Comprehensive use of almost every module, with the exception of Ambulatory.
- Office Practices use a separate EMR

# About our Cancer Center

---



**COMPREHENSIVE CANCER CARE**

- Robert and Audrey Luckow Pavilion
  - Satellite facility of The Valley Hospital
  - Incorporates The Valley-Mount Sinai Comprehensive Cancer Center
    - Ambulatory infusion center
      - 23 infusion chairs
      - 1800 oncology treatments per month
    - Valley Medical Group Oncology services
      - 11 practitioners
      - >14,000 total cancer patient visits per year

# Meditech Oncology Module

## Issues identified after building treatment plans

---

- Module imported diagnosis and indications from NCCN
  - Import Meditech STD Content Treatment Plans
  - Produced an excessive list of diagnoses and indications
    - Providers could not quickly find the desired regimen through the on screen clutter
    - Safety issue of providers choosing correct medications but doses are different
      - Ovarian cancer versus NSCLC
- Poor linkage to problems/diagnoses already filed prior to module being implemented

# OPTIMIZING ONCOLOGY TREATMENT PLANS

---

Issue #1: Ability to order too many cycles

# Best Practice and Quality Oncology Practice Initiative (QOPI) Standards

---

- QOPI Standards
  - 1.2.8 The chemotherapy treatment plan, including, at minimum, the patient diagnosis, drugs, doses, anticipated duration of treatment, and goals of therapy.
    - Can providers order more than the recommended cycles?
- Potential safety issue
  - Providers choosing metastatic plan (unlimited cycles) as opposed to neoadjuvant/adjuvant plans (limited cycles)

# Utilizing Maximum Cycles

---

- Created separate plans for neoadjuvant/adjuvant and metastatic regimens

 N.COL17.ONC.1	N.COL17.ONC.1	CapeOX Q21D
 N.COL17NA.ONC.1	N.COL17NA.ONC.1	CapeOX Q21D

# Utilizing Maximum Cycles, per indication

Neoadjuvant/adjuvant

Metastatic

N.COL17NA.ONC.1 - CapeOX Q21D [Ver 1.007]

Last Edit: 06/29/21 14

Main Cycles Orders MAR Sequence Items Associations

Chemotherapy  Treatment

\* Flowsheet Display Format By

* Cycle Description	* Length (Days)	First Start Date	Maximum Cycles	Override Maximum	Consecutive Repeats
CapeOx Q21D (3 months)	21	Ask	4	No	
CapeOx Q21D (6 months)	21	Ask	8	No	

+ → ← ↻ X

N.COL17.ONC.1 - CapeOX Q21D [Ver 1.049]

Last Edit: 06/29/21 14

Main Cycles Orders MAR Sequence Items Associations

Chemotherapy  Treatment

\* Flowsheet Display Format By

* Cycle Description	* Length (Days)	First Start Date	Maximum Cycles	Override Maximum	Consecutive Repeats
CapeOx Q21D (6 months)	21	Ask	8	Yes	

+ → ← ↻ X

# OPTIMIZING ONCOLOGY TREATMENT PLANS

---

Issue #2: Linkage by Diagnosis

# Too many plans to choose from!

- Different Indications still presented the same plan

The screenshot shows a software interface for selecting treatment plans. At the top, a search bar contains 'Lung cancer'. Below it, there are filters for 'Suggested', 'All', and 'Tumor Group'. A search bar for 'Plan' is also present. The main area is a table titled 'Select Plans for Diagnosis' with columns for 'Alias' and 'T C' buttons. The table lists various treatment regimens for Lung cancer, including recurrent therapy, advanced squamous cell carcinoma (first line), and metastatic disease. Each row has a checkbox and 'T C' buttons.

Plan	Alias	T	C
<input type="checkbox"/> Recurrent: Subsequent Therapy (3)			
<input type="checkbox"/> Atezolizumab q21D - metastatic [Ver 1]		T	C
<input type="checkbox"/> DOCETaxel-Ramucirumab - metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Nivolumab - metastatic [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Advanced - BRAF V600E mutation positive or NTRK gene fusion positive - First line (1)	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Advanced - EGFR/ALK/ROS1/BRAF negative/unknown and PD-L1 < 1% or unknown - First...	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Advanced - EGFR/ALK/ROS1/BRAF/NTRK + or PD-L1 + and EGFR/ALK - or unknown - Su...	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Advanced - PD-L1 expression > or = 1% and EGFR/ALK negative or unknown - First line (1)	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Continuation maintenance (1)	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Metastatic - BRAF V600E mutation positive or NTRK gene fusion positive - First line (1)	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Metastatic - EGFR/ALK/ROS1/BRAF negative/unknown and PD-L1 < 1% or unknown - Firs...	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Metastatic - EGFR/ALK/ROS1/BRAF/NTRK + or PD-L1 + and EGFR/ALK - or unknown - Su...	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound PACLitaxel - CARBOplatin: metastatic... [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CARBOplatin: metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Squamous cell carcinoma: Metastatic - EGFR/ALK/ROS1/BRAF/NTRK + or PD-L1 + and EGFR/ALK - /unknown - Subs...	*	T	C
<input type="checkbox"/> PEMEtrexed - maintenance q21D [Ver 1]		T	C
<input type="checkbox"/> PEMEtrexed-CARBOplatin + Pembrolizumab q21D [Ver 1]		T	C
<input type="checkbox"/> PEMEtrexed-Pembrolizumab - maintenance q21D [Ver 1]	*	T	C
<input type="checkbox"/> Pembrolizumab - Albumin-bound-PACLitaxel - CISplatin: metastatic... [Ver 1]	*	T	C
<input type="checkbox"/> Pembrolizumab - Nab-PACLitaxel - CISplatin - metastatic q21D [Ver 1]		T	C
<input type="checkbox"/> Pembrolizumab: metastatic/maintenance q21D [Ver 1]	*	T	C
<input type="checkbox"/> Squamous cell carcinoma: Metastatic - PD-L1 expression > or = 1% and EGFR/ALK negative or unknown - First line (1)			

# Post Cleanup

Diagnoses		Selected
Anemia due to chemotherapy	Dx/FNM	0
Anemia	Dx/TNM	0
Malignant neoplasm of upper lobe, left bronchus or lung	Dx/TNM	0

Suggested All Tumor Group

Plan  Keyboard Starts With Any Word

Select Plans for Diagnosis	Alias
<b>- ACUTE LYMPHOCYTIC LEUKEMIA: (2) Remission consolidation (1)</b>	
<input type="checkbox"/> CALGB 10403 Remission Consolidation Therapy (Course 2) [Ver 1]	T
<b>- ACUTE LYMPHOCYTIC LEUKEMIA: (3) Interim maintenance (1)</b>	
<input type="checkbox"/> CALGB 10403 Interim Maintenance Therapy (Course 3) [Ver 1]	T
<b>- ACUTE LYMPHOCYTIC LEUKEMIA: (4) Delayed intensification (1)</b>	
<input type="checkbox"/> CALGB 10403 Delayed Intensification Therapy (Course 4) [Ver 1]	I
<b>- ACUTE LYMPHOCYTIC LEUKEMIA: (5) Maintenance (1)</b>	
<input type="checkbox"/> CALGB 10403 Maintenance Therapy (Course 5) [Ver 1]	T P
<b>- ACUTE MYELOID LEUKEMIA: (1) APL Induction (3)</b>	
<input type="checkbox"/> Decitabine 20 mg/m2 (1-5) Q28D [Ver 1]	T C
<input type="checkbox"/> Low-Dose Cytarabine 20 mg/m2 (1-5,8-12) Q28D SubQ or IV [Ver 1]	T C
<input type="checkbox"/> Tretinoin (ATRA)/Arsenic - Induction [Ver 1]	T C
<b>- ACUTE MYELOID LEUKEMIA: (2) APL Consolidation (3)</b>	
<input type="checkbox"/> Decitabine 20 mg/m2 (1-5) Q28D [Ver 1]	T C
<input type="checkbox"/> Low-Dose Cytarabine 20 mg/m2 (1-5,8-12) Q28D SubQ or IV [Ver 1]	T C
<input type="checkbox"/> Tretinoin (ATRA)/Arsenic - Consolidation [Ver 1]	T C
<b>- AMYLOIDOSIS: (1) Primary treatment (1)</b>	
<input type="checkbox"/> Bortezomib/Cyclophosphamide/Dexamethasone + Daratumumab ... [Ver 1]	T C
<b>- AMYLOIDOSIS: (2) Previously treated (1)</b>	
<input type="checkbox"/> Daratumumab (IV/SubQ) Q28D [Ver 1]	T C
<b>- AMYLOIDOSIS: (3) Relapsed (1)</b>	
<input type="checkbox"/> Bortezomib/Cyclophosphamide/Dexamethasone + Daratumumab ... [Ver 1]	I C
<b>- ANAL: (1) Localized (3)</b>	
<input type="checkbox"/> CISplatin/Fluorouracil infusional w/concurrent radiation Q56D [Ver 1]	T C
<input type="checkbox"/> Capecitabine/MitoMYcin w/concurrent radiation Q42D [Ver 1]	T C
<input type="checkbox"/> Fluorouracil infusional/MitoMYcin w/concurrent radiation Q35D [Ver 1]	T C
<b>- ANAL: (2) Metastatic (8)</b>	
<input type="checkbox"/> CISplatin/Fluorouracil infusional Q21D or Q28D [Ver 1]	T C
<input type="checkbox"/> CISplatin/Fluorouracil Infusional w/concurrent radiation Q56D [Ver 1]	T C
<input type="checkbox"/> DCF modified Q14D [Ver 1]	T C
<input type="checkbox"/> FOLFCIS Q14D [Ver 1]	T C
<input type="checkbox"/> FOLFOX6 modified Q14D [Ver 1]	T C
<input type="checkbox"/> Nivolumab 240 mg Q14D or 480 mg Q28D [Ver 1]	T C
<input type="checkbox"/> Paclitaxel/CARBoplatin Q21D or Q28D [Ver 1]	T C

# Same Plan, lots of duplication

- Multiple Indications for a Plan resulted in Duplication of the same Plan on the selection list.
- Cause of Confusion – Am I ordering all those options?

The screenshot shows a software interface for selecting treatment plans. At the top, the diagnosis is 'Breast cancer in male'. Below this, there are filter buttons: 'Suggested', 'All', and 'Tumor Group'. A search bar is present with the text 'Plan'. To the right, there are buttons for 'Keyboard' and 'Starts With Any Wo'. The main area is a table titled 'Select Plans for Diagnosis'.

	Alias	
<b>Androgen deprivation therapy (ADT): Castration naive (1)</b>		
<input checked="" type="checkbox"/> Eligard [Ver 1]	*	T C
<input checked="" type="checkbox"/> Leuprolide - Prostate Cancer [Ver 1]		T C
<input checked="" type="checkbox"/> Lupron [Ver 1]	*	T C
<b>Androgen deprivation therapy (ADT): Castration resistant (1)</b>		
<input checked="" type="checkbox"/> Eligard [Ver 1]	*	T C
<input checked="" type="checkbox"/> Leuprolide - Prostate Cancer [Ver 1]		T C
<input checked="" type="checkbox"/> Lupron [Ver 1]	*	T C
<b>Androgen deprivation therapy (ADT): Clinically localized (1)</b>		
<input checked="" type="checkbox"/> Eligard [Ver 1]	*	T C
<input checked="" type="checkbox"/> Leuprolide - Prostate Cancer [Ver 1]		T C
<input checked="" type="checkbox"/> Lupron [Ver 1]	*	T C
<b>Androgen deprivation therapy (ADT): Regional disease (1)</b>		
<input checked="" type="checkbox"/> Eligard [Ver 1]	*	T C
<input checked="" type="checkbox"/> Leuprolide - Prostate Cancer [Ver 1]		T C
<input checked="" type="checkbox"/> Lupron [Ver 1]	*	T C

# Post Cleanup

- <b>PROSTATE: Androgen deprivation therapy (2)</b>		
<input type="checkbox"/> Goserelin 3.6 mg Q28D or 10.8 mg Q84D [Ver 1]	T	C
<input type="checkbox"/> Leuprolide acetate (Eligard) [Ver 1]	T	C
- <b>PROSTATE: Castration naive metastatic (1)</b>		
<input type="checkbox"/> DOCEtaxel 75 mg/m2 Q21D [Ver 1]	T	C
- <b>PROSTATE: Castration resistant metastatic (6)</b>		
<input type="checkbox"/> CABAziTaxel/PredniSONE Q21D [Ver 1]	T	C
<input type="checkbox"/> CARBOplatin/Etoposide 100 mg/m2 (1-3) Q21D or Q28D [Ver 1]	T	C
<input type="checkbox"/> CISplatin/Etoposide (1-3) Q21D [Ver 1]	T	C
<input type="checkbox"/> DOCEtaxel 50 mg/m2 (1, 15) Q28D [Ver 1]	T	C
<input type="checkbox"/> DOCEtaxel/CARBOplatin Q21D [Ver 1]	T	C
<input type="checkbox"/> Pembrolizumab 200 mg Q21D or 400 mg Q42D [Ver 1]	T	C
- <b>PULMONARY: (1) Induction (1)</b>		

# Diagnosis/Problem Maps

- Multiple Diagnosis linked to a Plan created the issue of duplication in the look up.
- How to streamline the Diagnosis Dictionary.
- Link all applicable problems to the main diagnosis.
- Reduced the Diagnosis Dictionary from 282 to 133 entries.

Diagnosis Dictionary - (NAH TEST - TEST) - Heeren,John (EST) | CHRONIC\_LEUKEMIA - Chronic Leukemia | Last Edit: 07/21/21 16:30

Main Clinics Items Forms/Instructions Intake

Diagnosis: CHRONIC\_LEUKEMIA

Mnemonic	CHRONIC_LEUKEMIA
Active	Yes
Name	Chronic Leukemia
Problem List Table Label	
Tumor Group	Leukemia
Nomenclature Map	IMO-PROB-91811

Problem Maps

Atypical chronic myeloid leukemia [IMO-PROB-29247789]
Chronic lymphocytic leukemia [IMO-PROB-36162]
Chronic myelomonocytic leukemia [IMO-PROB-36207]
T-cell chronic lymphocytic leukemia [IMO-PROB-703189]
Chronic myeloid leukemia [IMO-PROB-78964]

# OPTIMIZING ONCOLOGY TREATMENT PLANS

---

Issue #3: Indications

# Physician Feedback

Why are there so many options?

I don't need this much detail.


Consolidate the list.

The screenshot shows a software interface for selecting treatment plans. At the top, it displays 'Breast cancer in male' and 'Diagnoses'. Below this, there are buttons for 'Suggested', 'All', and 'Tumor Group'. A search bar is present with the text 'Plan'. To the right of the search bar are buttons for 'Keyboard', 'Starts With', and 'Any Word'. The main area is a table titled 'Select Plans for Diagnosis' with an 'Alias' column. The table lists various treatment regimens, each with a checkbox and 'T C' buttons. The regimens are grouped into categories such as 'Advanced: Initial Therapy - MSI-H/dMMR tumors (4)', 'Advanced: PD-L1 expression greater than or equal to 1% and EGFR/ALK negative or unknown - First line (2)', 'Advanced: PD-L1 expression greater than or equal to 1% and EGFR/ALK negative or unknown - Subsequent Therapy...', 'Advanced: Subsequent Therapy (14)', 'Advanced: Subsequent Therapy - HER Amplified and KRAS/NRAS Wild-Type Gene (2)', and 'Advanced: Subsequent Therapy - KRAS/NRAS/BRAF Wild Type Gene (9)'. Some rows have an asterisk in the 'Alias' column.

Select Plans for Diagnosis	Alias
<input type="checkbox"/> Advanced: Initial Therapy - MSI-H/dMMR tumors (4)	
<input type="checkbox"/> Nivolumab - Ipilimumab [Ver 1]	T C
<input type="checkbox"/> Nivolumab Q14D [Ver 1]	T C
<input type="checkbox"/> Nivolumab Q28D [Ver 1]	T C
<input type="checkbox"/> Pembrolizumab Q21D or Q42D [Ver 1]	T C
<input type="checkbox"/> Advanced: PD-L1 expression greater than or equal to 1% and EGFR/ALK negative or unknown - First line (2)	
<input type="checkbox"/> PAClitaxel-CARBOplatin-Pembrolizumab - metastatic q21D [Ver 1]	* T C
<input type="checkbox"/> PAClitaxel-CARBOplatin-Pembrolizumab q21D [Ver 1]	T C
<input type="checkbox"/> Pembrolizumab - metastatic - maintenance q21D [Ver 1]	* T C
<input type="checkbox"/> Pembrolizumab Q21D [Ver 1]	T C
<input type="checkbox"/> Advanced: PD-L1 expression greater than or equal to 1% and EGFR/ALK negative or unknown - Subsequent Therapy...	
<input type="checkbox"/> Pembrolizumab Q21D [Ver 1]	T C
<input type="checkbox"/> Advanced: Subsequent Therapy (14)	
<input type="checkbox"/> Atezolizumab q21D - metastatic [Ver 1]	T C
<input type="checkbox"/> CapeOX (Capecitabine + OXALiplatin) q21D [Ver 1]	T C
<input type="checkbox"/> CapeOX (Capecitabine/OXALiplatin) + Bevacizumab q21D [Ver 1]	T C
<input type="checkbox"/> DOCEtaxel-Ramucirumab - metastatic q21D [Ver 1]	T C
<input type="checkbox"/> FOLFIRI (5-FU/Leucovorin/Irinotecan) + Bevacizumab q14D [Ver 1]	T C
<input type="checkbox"/> FOLFIRI (5-FU/Leucovorin/Irinotecan) q14D [Ver 1]	T C
<input type="checkbox"/> FOLFIOX (5-FU Cont. Infusion/Leucovorin/OXALiplatin) + Bevacizu... [Ver 1]	T C
<input type="checkbox"/> Irinotecan - Bevacizumab q14days [Ver 1]	T C
<input type="checkbox"/> Irinotecan - Bevacizumab q21days [Ver 1]	T C
<input type="checkbox"/> Irinotecan day 1, 8 q21d [Ver 1]	T C
<input type="checkbox"/> Irinotecan q14days [Ver 1]	T C
<input type="checkbox"/> Irinotecan q21days [Ver 1]	T C
<input type="checkbox"/> Nivolumab - metastatic [Ver 1]	T C
<input type="checkbox"/> mFOLFOX6 [Ver 1]	* T C
<input type="checkbox"/> mFOLFOX6 + Bevacizumab [Ver 1]	* T C
<input type="checkbox"/> mFOLFOX6 Q14D [Ver 1]	T C
<input type="checkbox"/> Advanced: Subsequent Therapy - HER Amplified and KRAS/NRAS Wild-Type Gene (2)	
<input type="checkbox"/> Lapatinib - Trastuzumab q28D [Ver 1]	T C
<input type="checkbox"/> Pertuzumab - Trastuzumab q21D [Ver 1]	T C
<input type="checkbox"/> Advanced: Subsequent Therapy - KRAS/NRAS/BRAF Wild Type Gene (9)	
<input type="checkbox"/> FOLFIRI (5-FU/Leucovorin/Irinotecan) + Cetuximab q14D [Ver 1]	T C
<input type="checkbox"/> FOLFIRI (5-FU/Leucovorin/Irinotecan) + Panitumumab q14D [Ver 1]	T C
<input type="checkbox"/> FOLFIOX (5-FU Cont. Infusion/Leucovorin/OXALiplatin) + Cetuxim... [Ver 1]	T C

# Indication Dictionary Standard Content

- Plans display under the Indication from the plan
- Difficult to determine the link of Indication to Diagnosis.
- Excessive detail that the providers did not find beneficial




The screenshot shows a software interface with a search bar at the top. Below the search bar is a table with three columns: Name, Active, and Mnemonic. The table lists various medical indications and their corresponding active status and mnemonics.

Name	Active	Mnemonic
* Clinical Trials *	No	Z.TRIALS
Adenocarcinoma	No	ADN
Adenocarcinoma	No	OCC.ADN
Adenocarcinoma: ECOG 0-1	No	ADN.ECOG
Adenocarcinoma: ECOG 0-1	No	OCC.ADN.EC
Adenocarcinoma: MSI-H/dMMR	No	ADN.MSI
Adenocarcinoma: MSI-H/dMMR	No	OCC.ADN.MS
Adenocarcinoma: TMB-H	No	ADN.TMB
Adenocarcinoma: TMB-H	No	OCC.ADN.TM
Adjuvant (Residual Disease)	No	ADJ.RFS
Adjuvant Therapy	No	ADJ
Adjuvant: Dysgerminoma	No	ADJ.DYS
Adjuvant: EGFR/ALK/ROS1/BRAF positive...	No	NSC.ADJ+
Adjuvant: High Risk Disease - Subseque...	No	ADJ.HRSUB
Adjuvant: If positive margins and in the ...	No	SBA.ADJ
Adjuvant: Primary Invasive Triple Negati...	No	BRS.ADJTN
Advanced	No	ADV
Advanced or metastatic: Initial or subse...	No	SBA.ADV
Advanced or metastatic: Initial or subse...	No	SBA.ADV.MS
Advanced or metastatic: Subsequent the...	No	SBA.ADV.SU

# Indication Dictionary Post Cleanup

- Streamlined the Indication dictionary to the cancer type and stage of treatment.
- Inactivated 399 Indications
- Replaced with 200 Indications



The screenshot shows a software interface with a search bar at the top. Below the search bar is a table with three columns: Name, Active, and Mnemonic. The table lists various medical indications, such as ACUTE LYMPHOCYTIC LEUKEMIA and ACUTE MYELOID LEUKEMIA, with their respective active status and mnemonic codes.

Name	Active	Mnemonic
ACUTE LYMPHOCYTIC LEUKEMIA: (1) Ind...	Yes	ALL.1
ACUTE LYMPHOCYTIC LEUKEMIA: (2) Re...	Yes	ALL.2
ACUTE LYMPHOCYTIC LEUKEMIA: (3) Int...	Yes	ALL.3
ACUTE LYMPHOCYTIC LEUKEMIA: (4) Del...	Yes	ALL.4
ACUTE LYMPHOCYTIC LEUKEMIA: (5) Mai...	Yes	ALL.5
ACUTE MYELOID LEUKEMIA: (1) APL Ind...	Yes	AML.IND
ACUTE MYELOID LEUKEMIA: (2) APL Con...	Yes	AML.CONS
AMYLOIDOSIS: (1) Primary treatment	Yes	AMYL.PRI
AMYLOIDOSIS: (2) Previously treated	Yes	AMYL.PREV
AMYLOIDOSIS: (3) Relapsed	Yes	AMYL.REL
ANAL: (1) Localized	Yes	ANA.LOC
ANAL: (2) Metastatic	Yes	ANA.META
BLADDER NON-UROTHELIAL: (1) Adenoc...	Yes	BLAN.ADEN
BLADDER/UPPER GU/URETHRA: (1) Neoa...	Yes	BLAGU.NEO
BLADDER/UPPER GU/URETHRA: (2) Adju...	Yes	BLAGU.ADJ
BLADDER/UPPER GU/URETHRA: (3) Non-...	Yes	BLAGU.NON
BLADDER/UPPER GU/URETHRA: (4) Local...	Yes	BLAGU.MET
BLADDER: (1) Organ preserving	Yes	BLA.PRES
BLADDER: (2) Palliation	Yes	BLA.PALL
BONE: (1) Unresectable, metastatic, rec...	Yes	BONE.1

# Implementing Indication Dictionary Cleanup

Before

After

**N.NSC26.ONC.1 - PEMEtrexed q21D [Ver 1.025]** Last Edit: 12/08/20 15:06

Main Cycles Orders MAR Sequence Items Associations

Treatment Plan: N.NSC26.ONC.1  
Mnemonic: N.NSC26.ONC.1  
\* Active: Yes  
\* Name: PEMEtrexed q21D

Clinic: Oncology  
Clinical Trial:  Yes  No  
Custom Data Screen:   
BSA Method:

Override Drug Interactions:  Yes  No  
Override Duplicate Interactions:  Yes  No  
Oral Med Flowsheet Display:

Alias:   
Version 1.025  
\* Orderable:  Yes  No  
Comment:

Flowsheet Display:   
Orders Panel Label Sequence:

Restrict by Location: Infusion-LP  
Restrict by Provider:

Inpatient Treatment Plan Review Required By:   
Outpatient Treatment Plan Review Required By:

Plan Protocol Plan Citations Plan User Notes Cancel Save

**Diagnosis:** Non-small cell lung cancer

**Indication:** (greater than or equal to 50%) - Subsequent Therapy  
Nonsquamous cell carcinoma: Advanced, EGFR/ALK/...  
Nonsquamous cell carcinoma: Continuation mainten...

**N.NSC26.ONC.1 - PEMEtrexed 500 mg/m2 Q21D [Ver 1.038]** Last Edit: 09/21/21 09:03

Main Cycles Orders MAR Sequence Items Associations

Treatment Plan: N.NSC26.ONC.1  
Mnemonic: N.NSC26.ONC.1  
\* Active: Yes  
\* Name: PEMEtrexed 500 mg/m2 Q21D

Clinic: Oncology  
Clinical Trial:  Yes  No  
Custom Data Screen:   
BSA Method:

Override Drug Interactions:  Yes  No  
Override Duplicate Interactions:  Yes  No  
Oral Med Flowsheet Display:

Alias:   
Version 1.038  
\* Orderable:  Yes  No  
Comment:

Flowsheet Display:   
Orders Panel Label Sequence:

Restrict by Location: Infusion-LP  
Restrict by Provider:

Inpatient Treatment Plan Review Required By:   
Outpatient Treatment Plan Review Required By:

Plan Protocol Plan Citations Plan User Notes Cancel Save

**Diagnosis:** Non-small cell lung cancer

**Indication:** NSCLC: (8) Advanced, recurrent or metastatic - Non...

# Indications match Stage of Patient Therapy

Select Plans for Diagnosis	Alias	
<b>- BREAST: (1) Ovarian Suppression (2)</b>		
<input type="checkbox"/> Goserelin 3.6 mg Q28D [Ver 1]		T C
<input type="checkbox"/> Leuprolide Q28D or Q3months [Ver 1]		T C
<b>- BREAST: (2) Neoadjuvant - HER2 negative (13)</b>		
<input type="checkbox"/> AC + Pembro Q21D then PACLI(1,8,15)/CARBO(1,8,15) AUC 1.5/... [Ver 1]		T C
<input type="checkbox"/> AC + Pembrolizumab Q21D then PACLI(1,8,15)/CARBO AUC 5/Pe... [Ver 1]		T C
<input type="checkbox"/> AC Q21D [Ver 1]		T C
<input type="checkbox"/> CMF Q21D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D followed by DD PACLItaxel Q14D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D followed by weekly PACLItaxel [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D then PACLItaxel 80 mg/m2 Q7D [Ver 1]		T C
<input type="checkbox"/> DOCEtaxel 75 mg/m2/CARBOplatin AUC 6 Q21D [Ver 1]		T C
<input type="checkbox"/> PACLItaxel 80 mg/m2 (1,8,15)/CARBOplatin AUC 1.5-2 (1,8,15) Q... [Ver 1]		T C
<input type="checkbox"/> PACLItaxel 80 mg/m2 (1,8,15)/CARBOplatin AUC 6 Q21D [Ver 1]		T C
<input type="checkbox"/> TAC Q21D [Ver 1]		T C
<input type="checkbox"/> TC Q21D [Ver 1]		T C
<b>- BREAST: (2) Neoadjuvant - HER2 positive (6)</b>		
<input type="checkbox"/> DDAC Q14D followed by PACLItaxel(1,8,15)/Trastuzumab Q21D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D followed by Pertuzumab+Trastuzumab+PACLItaxel(we... [Ver 1]		T C
<input type="checkbox"/> DOCEtaxel/Cyclophosphamide + Trastuzumab Q21D [Ver 1]		T C
<input type="checkbox"/> Pertuzumab + Trastuzumab + PACLItaxel 80 mg/m2 (1,8,15) Q21D [Ver 1]		T C
<input type="checkbox"/> TCH Q21D [Ver 1]		T C
<input type="checkbox"/> TCHP Q21D [Ver 1]		T C
<b>- BREAST: (3) Adjuvant - HER2 negative (11)</b>		
<input type="checkbox"/> AC + Pembro Q21D then PACLI(1,8,15)/CARBO(1,8,15) AUC 1.5/... [Ver 1]		T C
<input type="checkbox"/> AC + Pembrolizumab Q21D then PACLI(1,8,15)/CARBO AUC 5/Pe... [Ver 1]		T C
<input type="checkbox"/> AC Q21D [Ver 1]		T C
<input type="checkbox"/> CMF Q21D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D followed by DD PACLItaxel Q14D [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D followed by weekly PACLItaxel [Ver 1]		T C
<input type="checkbox"/> DDAC Q14D then PACLItaxel 80 mg/m2 Q7D [Ver 1]		T C
<input type="checkbox"/> PACLItaxel 80 mg/m2 (1,8,15)/CARBOplatin AUC 1.5-2 (1,8,15) Q... [Ver 1]		T C

# Customer (Physician) Satisfaction !

---



# Optimizing Oncology Treatment Plans

---

[JHeeren@Valleyhealth.com](mailto:JHeeren@Valleyhealth.com)

[DTurber@Valleyhealth.com](mailto:DTurber@Valleyhealth.com)

## QUESTIONS?